Document Type
Article
Publication Date
11-19-2024
Abstract
BACKGROUND: Interleukin-37 (IL-37) has anti-inflammatory properties in innate and adaptive immunity. Patients with multiple sclerosis (MS), an autoimmune inflammatory demyelinating disease of the central nervous system (CNS), have increased serum levels of IL-37. However, it is unknown whether IL-37 has an inhibitory effect on ongoing autoimmune neuroinflammation, thus offering a potential MS therapy.
AIM: Here, we examined the effect of IL-37 in an experimental autoimmune encephalomyelitis (EAE) model after disease onset to determine if it was protective.
FINDINGS: IL-37-treated mice developed a less severe disease than control mice, with reduced demyelination as determined by increased expression of myelin basic protein. IL-37 suppressed inflammation by decreasing infiltration of CD4 + T cells into the CNS and increasing the frequency of regulatory T cells, while IL-10 expression by CD4 + T cells decreased over time in the CNS.
CONCLUSION: Our findings confirm the immunomodulatory role of IL-37 in CNS inflammation during ongoing disease, thus indicating the potential of IL-37 as an inhibitory reagent for MS therapy.
Recommended Citation
Yazdani, Reza; Naziri, Hamed; Azizi, Gholamreza; Ciric, Bogoljub; Askari, Mozhde; Moghadam-Ahmadi, Amir; Aseervatham, Jaya; Zhang, Guang-Xian; and Rostami, Mohamad, "IL-37 Suppresses CNS Autoimmunity by Increasing the Frequency of Treg Cells and Reducing CD4 + T Cell-Derived IL-10 Production" (2024). Department of Neurology Faculty Papers. Paper 351.
https://jdc.jefferson.edu/neurologyfp/351
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
PubMed ID
39563375
Language
English
Comments
This article is the author's final published version in Journal of Neuroinflammation, Volume 21, Issue 1, 2024, Article number 301.
The published version is available at https://doi.org/10.1186/s12974-024-03295-1.
Copyright © The Author(s) 2024